AIM ImmunoTech Overview
Latest P/E ratio for AIM ImmunoTech: -0.31 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.31
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, AIM shows a P/E ratio of -0.31. That is below the Healthcare sector average of 26.36. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 26.36. AIM ImmunoTech is at -0.31, which is lower that average. That is roughly 101.2% below the sector mean. Use the comparison chart on this page to see how AIM stacks up against individual peers as well.
Investors watch AIM's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. AIM ImmunoTech's latest reading is -0.31. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has AIM ImmunoTech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -0.31) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 26.36, while AIM is at -0.31. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
